Inscripta is a gene-editing technology company that puts researchers in control by making it easy for them to get all they need for cutting-edge, forward cell-engineering. These tools include a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that will significantly increase the speed and efficiency of multiplexed, precision gene editing. By removing the barriers to forward cell engineering and gene-editing research, Inscripta will usher in a new era of advances to revolutionize how we feed, fuel, and heal humanity.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/28/18 | $55,500,000 | Series C |
Merieux Developpement Paladin Capital Group | undisclosed |
| 04/04/19 | $20,000,000 | Series C |
Foresite Capital Merieux Developpement MLS Capital NanoDimension Paladin Capital Group Venrock | undisclosed |
